Tiziana Life Sciences PLC (LON:TILS)‘s stock had its “speculative buy” rating restated by stock analysts at Beaufort Securities in a report released on Wednesday, May 24th. They currently have a GBX 400 ($5.10) price target on the biotechnology company’s stock. Beaufort Securities’ price objective suggests a potential upside of 131.88% from the company’s current price.
Shares of Tiziana Life Sciences PLC (LON TILS) remained flat at GBX 172.50 during midday trading on Wednesday. The company had a trading volume of 703 shares. The company’s market capitalization is GBX 162.83 million. Tiziana Life Sciences PLC has a one year low of GBX 102.06 and a one year high of GBX 240.00. The stock’s 50-day moving average is GBX 195.64 and its 200-day moving average is GBX 195.83.
WARNING: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/06/20/tiziana-life-sciences-plcs-tils-speculative-buy-rating-reiterated-at-beaufort-securities-updated-updated-updated.html.
Tiziana Life Sciences PLC Company Profile
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.